.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Citi
Boehringer Ingelheim
Chinese Patent Office
Deloitte
QuintilesIMS
Daiichi Sankyo
Healthtrust
Merck
Novartis

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,781,401

« Back to Dashboard

Details for Patent: 7,781,401

Title:Glucagon-like peptide-2 analogs
Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J. (Toronto, CA), Crivici; Anna E. (San Diego, CA), Sumner-Smith; Martin (Bolton, CA)
Assignee: NPS Pharmaceuticals, Inc. (Bedminster, NJ)
Filing Date:Nov 14, 2002
Application Number:10/293,941
Claims:1. A GLP-2 analog of SEQ ID NO:2, or pharmaceutically acceptable salt thereof, having intestinotrophic activity, wherein said analog comprises at least one amino acid substitution at sites selected from the group consisting of 5, 7, 25, 30, and 33, wherein site 5 may be substituted with Thr or Ala, site 7 may be substituted with Ala, site 25 may be substituted with Phe or Tyr, site 30 may be substituted with Arg, and site 33 may be substituted with Asn or Glu.

2. A pharmaceutical composition comprising a mammalian GLP-2 analog, or pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable carrier.

3. A method for promoting the growth of small bowel tissue in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 2 to promote the growth of small bowel tissue.

4. The method for the treatment of a gastrointestinal disease, comprising administering to a patient having the gastrointestinal disease an effective amount of a pharmaceutical composition according to claim 2.

5. The method of claim 4 wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, radiation enteritis, infectious or post-infectious enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or other chemotherapeutic agents, and short bowel syndrome.

6. The method of claim 5 wherein the gastrointestinal disease is short bowel syndrome.

7. The method of claim 5 wherein the gastrointestinal disease is small intestinal damage due to toxic or other chemotherapeutic agents.

8. The method of claim 5 wherein the gastrointestinal disease is radiation enteritis.

9. A method for enhancing the nutritional absorption of the small intestine in a patient in need thereof, comprising administering to the patient an effective amount of the pharmaceutical composition according to claim 2.

10. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 5 of SEQ ID NO: 2 is substituted with Thr.

11. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 5 of SEQ ID NO: 2 and the amino acid at position 7 of SEQ ID NO: 2 are substituted with Ala.

12. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 25 of SEQ ID NO: 2 is substituted with Phe.

13. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 25 of SEQ ID NO: 2 is substituted with Tyr.

14. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 30 of SEQ ID NO: 2 is substituted with Arg.

15. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 33 of SEQ ID NO: 2 is substituted with Glu.

16. The mammalian GLP-2 analog of claim 1 wherein the amino acid at position 33 of SEQ ID NO: 2 is substituted with Asn.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Express Scripts
Chinese Patent Office
Queensland Health
Mallinckrodt
Colorcon
McKinsey
Julphar
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot